Background: Lung cancer is the leading cause of cancer-related death. NSCLC accounts for 80–90% of cases. In young patients, adenocarcinoma is the most frequent histotype and 3–7% expresses the rearrangement of ALK oncogene, sensitive to TKIs. Crizotinib is the first ALK inhibitor approved by the FDA. Case: We present a case of a 17-year-old male with metastatic treatment-naïve ALK-positive adenocarcinoma. He was treated with crizotinib and obtained a prolonged response with PFS of 33 months. Conclusion: Crizotinib can be extremely effective in adolescents with treatment-naïve ALK-positive NSCLC but fail to prevent a central nervous system relapse. Resistance mechanisms need to be investigated.
Megaro, G., Miele, E., Spinelli, G. P., Alessi, I., Del Baldo, G., Cozza, R., Russo, I., De Pasquale, M. D., Cefalo, M. G., Toma, P., Carai, A., Di Ruscio, V., De Ioris, M. A., Mastronuzzi, A., Long-term response to crizotinib in a 17-year-old boy with treatment-naïve ALK-positive non-small-cell lung cancer, <<CANCER REPORTS>>, 2021; 5 (3): 1-4. [doi:10.1002/cnr2.1483] [https://hdl.handle.net/10807/330096]
Long-term response to crizotinib in a 17-year-old boy with treatment-naïve ALK-positive non-small-cell lung cancer
Carai, AndreaWriting – Review & Editing
;Mastronuzzi, AngelaUltimo
Writing – Review & Editing
2022
Abstract
Background: Lung cancer is the leading cause of cancer-related death. NSCLC accounts for 80–90% of cases. In young patients, adenocarcinoma is the most frequent histotype and 3–7% expresses the rearrangement of ALK oncogene, sensitive to TKIs. Crizotinib is the first ALK inhibitor approved by the FDA. Case: We present a case of a 17-year-old male with metastatic treatment-naïve ALK-positive adenocarcinoma. He was treated with crizotinib and obtained a prolonged response with PFS of 33 months. Conclusion: Crizotinib can be extremely effective in adolescents with treatment-naïve ALK-positive NSCLC but fail to prevent a central nervous system relapse. Resistance mechanisms need to be investigated.
| File | Dimensione | Formato | |
|---|---|---|---|
|
Cancer Reports - 2022 - Megaro - Long‐term response to crizotinib in a 17‐year‐old boy with treatment‐na ve ALK‐positive.pdf
accesso aperto
Tipologia file ?:
Versione Editoriale (PDF)
Licenza:
Creative commons
Dimensione
6.07 MB
Formato
Adobe PDF
|
6.07 MB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
